Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers

Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers

Background Durvalumab (D; anti-programmed cell death ligand 1 (PD-L1)) monotherapy or in combination with tremelimumab (T; anti-cytotoxic T lymphocyte antigen-4 (CTLA-4)) have demonstrated efficacy in advanced cancers. However, higher incidences of adverse events (AEs) and immune-mediated AEs (imAEs...

Full description

Saved in:
Bibliographic Details
Main Authors: Mayur Patel, John Kurland, Claire Morgan, Cathy O’Brien, Pamela Concepcion, Gary J Doherty, Stephan Hois, Alejandra Negro, Dejan Pavlovic, Karen A Robbins
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e011140.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e011140.full

Similar Items